Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
MNTA Revenue (TTM) data by YCharts ... Investors can never be certain that generic competition lawsuits will be decided in their biotech stock's favor, but they shouldn't panic when lawsuits are disclosed. While generic competition is a real …
Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) was started as Overweight at JPMorgan on Friday, and the firm assigned a $26 price target. This implied 46% upside from the prior $17.76 close, although Momenta shares rose …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNTA at https://www.zacks.com/ap/MNTA Keywords: Momenta …
Shares of Momenta Pharmaceuticals Inc. MNTA were down 12.6% after the company reported disappointing ... However, revenues were down 17.3% from the year-ago quarter. Momenta’s stock has decreased 15.1% year to date compared …
Momenta Pharmaceuticals (NASDAQ:MNTA) shifted sharply into reverse in early trading ... Momenta's multiple sclerosis treatment. Analysts that follow the stock had expected revenue of $30.42mln. The shares shed 8.3% at $10.55. “The …
Momenta Pharmaceuticals Inc. (MNTA) reported 4Q earnings of $41.5 million, or 60 cents a share, compared to a loss of $29.2 million, or 43 cents per share, a year ago. The Cambridge, Massachusetts-based company’s fourth-quarter …
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version …